Thursday, October 22, 2026 Published by AdvancedCare USA Inc.

TheraNews
Subscribe

Archive summary Clinical & research

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the presentation of ne

Summary of reporting by financialcontent 1 min read Markdown

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

Originally reported by financialcontent. Read more

Source: https://www.financialcontent.com/article/bizwire-2026-6-6-corcept-presents-new-data-at-ada-improved-outcomes-in-patients-receiving-a-glp-1-with-difficult-to-control-type-2-diabetes-and-hypercortisolism-treated-with-korlym

Newsletter

The weekly digest

Weekly digest of US behavioral health policy and regulation, source-linked and practitioner-edited. Free; unsubscribe in one click.